查詢結果分析
相關文獻
- Glucose and Insulin Infusion Versus Kayexalate for the Early Treatment of Non-oliguric Hyperkalemia in Very-Low-Birth-Weight Infants
- The Use of Prophylactic Intravenous Immunoglobulin Therapy in Very Low Birthweight Infants
- Staphylococcus capitis Bacteremia of Very Low Birth Weight Premature Infants at Neonatal Intensive Care Units: Clinical Significance and Antimicrobial Susceptibility
- Efffect of Erythromycin on Feeding Intolerance in Very Low Birth Weight Infants: A Preliminary Observation
- The Anesthetic Management of A Preterm Infant Weighing 500 Grams Undergoing Ligation of Patent Ductus Arteriosus--A Case Report
- 極低體重早產兒肺出血之探討
- Intraventricular Hemorrhage, Periventricular Leukomalacia and Hypoglycemia in Very Low Birth Weight Infants: Relationship to Neurodevelopment at Two Years of Age
- Glucose-Insulin Infusion for the Early Treatment of Non-oliguric Hyperkalemia in Extremely-Low-Birth-Weight Infants
- Sepsis in the Very Low Birth Weight Infants in Taiwan
- 談日本1000公克以下極低體重早產兒7-9歲的追蹤成果
頁籤選單縮合
題名 | Glucose and Insulin Infusion Versus Kayexalate for the Early Treatment of Non-oliguric Hyperkalemia in Very-Low-Birth-Weight Infants=葡萄糖及胰島素早期連續輸注相較於陽離子交換劑於極低體重早產兒合併非寡尿性高血鉀症之應用 |
---|---|
作者 | 胡博翔; 蘇百弘; 彭慶添; 蔡長海; | 書刊名 | 臺灣兒科醫學會雜誌 |
卷期 | 40:5 民88.09-10 |
頁次 | 頁314-318+359 |
分類號 | 417.5171 |
關鍵詞 | 極低體重早產兒; 非寡尿性高血鉀症; 胰島素輸注; VLBW infant; Non-oliguric hyperkalemia; Regular insulin infusion; |
語文 | 英文(English) |
中文摘要 | 四十位在出生後數日內發生非寡尿性高血鉀症之極低體重早產兒分別隨機接受持 續性胰島素輸注(胰島素組)及Kayexalate灌腸(Kayexalate組)治療。本研究以血鉀濃度超 過6mEq/L視為高血鉀並開始治療。所有早產兒在研究過程中並未接受輸血治療,而出生時亦 無缺氧或窒息。持續性胰島素輸注的方式為10-15克葡萄糖配合1單位的胰島素並保持葡萄 糖輸注速率至少每公斤體重每分鐘6亳克。而Kayexalate的給予方式為每公斤體重1克,並 且每四小時灌腸一次。血鉀連續6小時在正常範圍內後停止所有治療。本研究中,平均懷孕 週數在胰島素組及Kayexalate組分別為27.4±1.8週及28.4±2.4週。平均出生體重為 935±259克及1065±214克。發生高血鉀症之年紀為出生後24.6±8.2及22.2±8.1小時。高 血鉀症發生前平均8小時之尿量為每公斤每分鐘5.3±1.4毫升及5.5±0.9毫升。治療後,高 血鉀症持續時間以胰島素組較短(24.6±14.9 vs. 38.6±13.3小時),並具有統計意義 (p=0.009)。最高血鉀濃度分別為7.4±0.8及7.4±0.6mEq/L。發生第二度以上腦室出血之比 例分別為15%(3/20),及50%(10/20),亦具統計意義(p=0.018)。但在心率不整發生率上則無 明顯差異(5%(1/20) vs. 10%(2/20))。我們的研究顯示,極低體重早產兒之非寡尿性高血鉀 症可以使用早期持續性胰島素輸注治療而有效縮短高血鉀症持續時間並減少嚴重腦室出血的 機率。 |
英文摘要 | Forty very low birth weight (VLBW) infants with non-oliguric hyperkalemia in the first few days after birth were enrolled in this study. They were randomly divided into 2 groups, regular insulin (RI) infusion group and kayexalate resin enema group. Therapy was administered when serum potassium level was greater than 6 mEq/L. None of these infants received blood transfusion during this study course. In RI group (n=20), the ratio of infusion glucose to regular insulin was 10-15gm glucose to I unit RI, and the glucose infusion rate was maintained at least 6mg/Kg/mm. In Kayexalate group (n=20 ), the dose of Kayexalate was 1gm/Kg body weight given rectally every four hours. All treatment discontinued after the serum potassium level returned to normal for 6 hours. The mean gestational ages were 27.4 ± 1.8 weeks in RI group and 28.4 ± 2.4 weeks in Kayexalate group, respectively. Mean birth weights were 935 ± 259 gm (RI) and 1065 ± 214 gm (Kayexalate). The ages at onset of hyperkalemia were 24.6 ± 8.2 (RI) and 22.2 ± 8.1 (Kayexalate) hours after birth. The mean urine outputs during the 8-hour interval prior to development of hyperkalemia were 5.4 ± 1.3(RI) and 5.5 ± 0.9 (Kayexalate) ml//kg/min. The durations of hyperkalemia were 26.4 ± 14.9 (RI) and 38.6 ± 13.3 (Kayexalate) hours. The peak serum potassium levels during therapy were 7.3 ± 0.9 and 7.4 ± 0.6 mEq/L. The incidences of grade II and above intra ventricular hemorrhage (IVH) were 15% (3/20) and 50% (10/20). The incidences of cardiac dysrhythmia were 5% (1/20) and 10% (2/20). Significantly shorter duration of non-oliguric hyperkalemia and lower incidence of IVH were noted in RI group, but there were no differences in the peak potassium level or the incidence of cardiac dysrhythmia between these two groups. We conclude that to use early continuous regular insulin infusion therapy for the treatment of non-oliguric hyperkalemia in VLBW infants is more effective than kayexalate in decreasing the duration of hyperkalemia and reducing the incidence of intraventricular hemorrhage. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。